文章摘要
丙型肝炎病毒核酸定量检测性能验证及评价
Performance verification and evaluation for hepatitis C virus nucleic acid quantitative detection
  
DOI:10.3969/j.issn.1007-8134.2019.05.003
中文关键词: HCV RNA  定量检测  实时荧光定量PCR  性能验证
英文关键词: HCV RNA  quantitative assay  real-time fluorescence quantitative PCR  performance verification
基金项目:首都医科大学附属北京地坛医院院内科研基金“育苗计划”项目(DTYM201803)
作者单位
郭 杰 首都医科大学附属北京地坛医院检验科 
曲 沛 首都医科大学附属北京地坛医院检验科 
李韦杰 首都医科大学附属北京地坛医院检验科 
周 宇 首都医科大学附属北京地坛医院检验科 
郭晶晶 首都医科大学附属北京地坛医院检验科 
焦炳欣 首都医科大学附属北京地坛医院检验科 
王雅杰 首都医科大学附属北京地坛医院检验科 
摘要点击次数: 543
全文下载次数: 380
中文摘要:
      目的 验证丙型肝炎病毒核酸定量检测试剂检出限发生改变时,能否达到厂家制定的分析指标。 方法 参照《临床实验室对商品定量试剂盒》WS/T 420-2013的性能验证方案,采用HCV RNA标准物质和首都医科大学附属北京地坛医院收集的不同浓度的临床标本,对丙型肝炎病毒核酸定量检测试剂的正确度、精密度、线性、检测限和抗干扰能力等参数进行方法学性能验证和评价。结果 在正确度验证中,回归方程为y=0.9881x-0.0972,R=0.998>0.95,检测值与参考值高度相关。在精密度验证中,高浓度和低浓度标本的批内精密度CV值(1.86%,2.64%)及批间精密度CV值(1.44%,2.36%)均≤5%,符合要求。在线性验证中,在2.50E+2~5.00E+7 IU/ml分析测量线性范围良好。在检测限验证中,重复检测浓度50 IU/ml样本30次,其中27次检出阳性,阳性率为90%(27/30),符合临床要求。在抗干扰能力验证中,加入干扰物质混合后的血清与混合前血清定值比较,绝对偏差均<±0.5 lg,检测结果符合临床需求。结论 当试剂盒的检出限发生改变时,实验室应重点对该修改项的分析性能进行充分评估,以判断结果能否达到厂家制定的分析指标。同时依据卫生行业标准对该试剂其余性能指标进行验证。
英文摘要:
      Objective To validate whether the performance of hepatitis C virus nucleic acid quantitative assay kit matches the analytical performance promised by the manufacturer at changed detection limits. Methods According to the performance validation program based on the WS/T420-2013 protocol of the Clinical Laboratory for Commercial Quantification Kit, the verification procedure was performed by using HCV RNA standards for reference and clinical specimens of different concentrations that were collected from Beijing Ditan Hospital affiliated to Capital Medical University. The performance of hepatitis C virus nucleic acid quantitative assay kit was methodologically verified and evaluated through detecting the accuracy, precision, linearity, detection limit and anti-interference ability of reagents. Results In the accuracy verification, the regression equation was y=0.9881x-0.0972, R=0.998>0.95, and the detected value was highly correlated with the reference value. In the precision verification, the intra-assay precision %CV value (1.86%, 2.64%) and the inter-assay precision %CV value (1.44%, 2.36%) of both high-concentration and low-concentration specimens were all≤5%, which met the requirements. In the linearity verification, the linear range of 2.50E+2 to 5.00E+7 IU/ml was valid. In the detection limit verification, samples at a concentration of 50 IU/ml were repeatedly measured 30 times, and 27 of the test results were positive, with a positive rate of 90% (27/30), which met the clinical requirements. In the anti-interference ability verification, the test values of serum samples with or without interfering substances were compared, and the absolute deviation of tests was less than ±0.5 lg, which met the clinical requirements. Conclusions When detection limits of an assay kit are revised, the laboratory should focus on a comprehensive evaluation of the analytical performance of the revised items, to judge whether the results match the analytical performance claimed by the manufacturer. At the same time, all other performance indicators of the reagents are validated according to the health industry standards.
HTML   查看全文   下载PDF阅读器
关闭